1. Home
  2. VTR vs KVUE Comparison

VTR vs KVUE Comparison

Compare VTR & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ventas Inc.

VTR

Ventas Inc.

HOLD

Current Price

$87.68

Market Cap

41.1B

Sector

Real Estate

ML Signal

HOLD

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$17.82

Market Cap

34.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTR
KVUE
Founded
1983
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Specialty Chemicals
Sector
Real Estate
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
41.1B
34.9B
IPO Year
2005
2023

Fundamental Metrics

Financial Performance
Metric
VTR
KVUE
Price
$87.68
$17.82
Analyst Decision
Buy
Buy
Analyst Count
13
11
Target Price
$84.77
$19.73
AVG Volume (30 Days)
2.2M
27.0M
Earning Date
01-01-0001
05-19-2026
Dividend Yield
2.37%
4.64%
EPS Growth
184.21
40.74
EPS
0.54
0.76
Revenue
$5,833,980,000.00
$15,124,000,000.00
Revenue This Year
$12.42
$4.80
Revenue Next Year
$8.32
$2.52
P/E Ratio
$162.48
$23.58
Revenue Growth
18.47
N/A
52 Week Low
$60.15
$14.02
52 Week High
$88.23
$25.17

Technical Indicators

Market Signals
Indicator
VTR
KVUE
Relative Strength Index (RSI) 69.40 45.07
Support Level $66.18 $17.14
Resistance Level N/A $19.07
Average True Range (ATR) 1.41 0.30
MACD -0.12 -0.14
Stochastic Oscillator 90.53 26.10

Price Performance

Historical Comparison
VTR
KVUE

About VTR Ventas Inc.

Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.

Share on Social Networks: